To meet increasing demand, CSL Behring has announced plans for a 185 million euro ($203 million) expansion in Marburg, Germany, where the global biotech already has its largest research and production facility.
The expansion, expected to be completed in 2023, will support production of the company’s treatments for hereditary angioedema (HAE), a rare disease that causes dangerous swelling episodes.
"With an efficient, seamless production chain and the new, state-of-the-art plant, we can once again significantly increase our production capacity. This puts us in a very good position for the future," said Managing Director and Site Manager Michael Schröder.
At facilities around the world, CSL Behring develops and manufactures treatments for patients who have rare and chronic diseases, such as hemophilia and primary immune deficiency. The Marburg expansion, which will require an additional 50 workers, piggybacks on another construction project already underway: a plasma fractionation plant expected to start operating in 2022.
Also in Marburg, a university town north of Frankfurt, CSL Behring recently celebrated the groundbreaking of an "Office of the Future,” which will provide 600 state-of-the-art work stations in a building heated and cooled by environmentally friendly geothermal energy. Plans for the green building, to open in 2022, also include a bicycle parking lot and two charging stations for electric vehicles.
